Fidelity SPDR Advertisement
Home > Boards > US Listed > Medical - Drugs >

Provectus Biopharmaceuticals Inc. (PVCT)

Add PVCT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Gulfbreeze, Ovidius, buccaneer1961, TOB, David Fowler
Search This Board:
Last Post: 8/21/2014 1:26:18 PM - Followers: 164 - Board type: Free - Posts Today: 0

This board acts as a portal for PVCT investors, and retains the right to refuse service to individuals not in compliance with reasonable, responsible, and intelligible posting practices.

PVCT on YouTube...

Letter from the CEO Craig Dee's

We are a group of dedicated and entrepreneurial scientists, working together for the past 10 years, engaged in developing breakthrough technologies for cancer and other serious diseases. Our primary goal at Provectus is to develop alternative treatments that are safer, more effective, less invasive and more economical than conventional therapies.

Our Provectus Pharmatech division develops ethical pharmaceuticals for oncology and dermatology. Looking first to oncology, our novel drugs are designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing systemic side effects. In particular, our focus is on melanoma, breast and liver cancers – among the most difficult cancers to treat using conventional methods. We are very excited about the Phase I clinical trials of Provecta™ that began in 2005 for melanoma and breast cancer, and we are expanding to include liver cancer patients soon.

Targeting abnormal or diseased cells is also the approach we use in designing proprietary treatments for dermatological diseases, in particular, chronic, severe cases of psoriasis, eczema and acne. We anticipate that Phase II clinical trials of our topical agent Xantryl™ for psoriasis and eczema will begin soon. In addition, certain skin cancers may be targeted and treated more safely and effectively using Xantryl™.

In addition to our core pharmaceutical work, Provectus has developed a number of intellectual properties and technologies in the areas of medical devices and biotechnologies. Rather than dilute the efforts of Pharmatech, we are actively pursuing licensure, co-development, spin-offs and joint ventures of these technologies via our divisions Provectus Devicetech and Provectus Biotech. Devicetech encompasses both cosmetic and therapeutic treatments, with key attention to developing laser-based products to treat melanoma. Biotech is concentrating on producing vaccines to prevent certain cancers and other serious diseases, as well as detecting new viruses that could be associated with the onset of such diseases.

Our fourth division, Pure-ific Corp., is prepped to be sold or spun off to further develop its over-the-counter products. We are introducing professional skincare products for disposable glove users, and novel retail products for personal hygiene. In addition, we will be introducing an OTC product for acne sufferers.

We are proud of our intellectual capital at Provectus. We hold 15 U.S. patents in the pharmaceutical, medical device and biotech fields, with 19 additional patent applications in the works.

Provectus is a significant, emerging player in the huge and growing pharmaceutical industry. We believe in our potential to improve health care worldwide, using breakthrough products that are easy to manufacture and license, and economical to use. We appreciate your interest in our company, and welcome your comments and questions.

Craig Dees, Ph.D., CEO
Provectus Pharmaceuticals

PVCT 6 months chart:

Technical analysis:

PVCT News:



PVCT insiders transactions:


Drug Delivery Technology magazine special feature article "Revisiting Intralesional Delivery of Cancer Treatment", by Provectus CEO Craig Dees, Ph.D., compares Provectus’ novel cancer drugs to current cancer treatments.

May 17, 2007
Professor Peter Hersey, M.D. comments on PV-10 and a patient's response
Professor Peter Hersey, M.D., a professor of oncology at the University of Newcastle and Medical and Research Director of the Newcastle Melanoma Unit, comments on PV-10 and a patient's response.

Video can be viewed here.

This 15-minute clip follows the progress of an 86-year-old man treated with the drug. Prior to his treatment, his melanoma was so unresponsive to the current standard of care, including numerous invasive operations and toxic chemotherapy, that he was given only months to live.

Video can be viewed here.
Contact Info

Telephone: +1 (865) 769-4011
Fax: +1 (865) 769-4013

Mailing Address:
Provectus Pharmaceuticals, Inc.
7327 Oak Ridge Hwy
Knoxville, TN 37931 USA

Transfer Agent:
(i.e. stockholder records, transfer, change of address, etc.)
Atlas Stock Transfer
5899 South State Street, Suite # 24
Murray, UT 84107
Telephone: +1 (801) 266-7151
Fax: +1 (801) 262-0907

Investor Relations:
Joseph Kessler
The Investor Relations Group
11 Stone St., 3rd fl
New York, NY 10004
Telephone: 212-825-3210
Fax: 212-825-3229

Public Relations:
The Investor Relations Group
Janet Vasquez
Telephone: 212-825-3210

Investment Advisor:
Damon Testaverde
Network 1 Financial Securities
Telephone: +1 (800) 205-8031
Share Statistics
45.45 m
35.35 m

Non-Corp. Insider Hold'gs:
22.20% (as of 4/1/07)

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
PVCT News: Current Report Filing (8-k) 05/27/2014 03:45:39 PM
PVCT News: Current Report Filing (8-k) 05/23/2014 02:19:35 PM
PVCT News: Current Report Filing (8-k) 05/21/2014 03:32:59 PM
PVCT News: Amended Statement of Changes in Beneficial Ownership (4/a) 05/20/2014 05:20:44 PM
PVCT News: Statement of Changes in Beneficial Ownership (4) 05/20/2014 06:08:15 AM
#3564  Sticky Note Provectus SEC Filings... Gulfbreeze 05/01/14 12:10:06 AM
#3563  Sticky Note PLEASE STICKY THIS INFORMATION laxerpro22 04/30/14 11:21:55 PM
#6366   Thanks for the translation cav1 08/21/14 01:26:18 PM
#6365   New blog Post In News Section vorlon1966 08/21/14 12:12:42 PM
#6364   Translation according to my computer... Itsallriggedanyways 08/21/14 11:25:35 AM
#6363   That's it, what is that? cav1 08/21/14 10:48:18 AM
#6362   Chinese? you mean like this? 236T568 08/21/14 10:28:24 AM
#6361   Anyone know how to read Chines? I received cav1 08/21/14 10:20:53 AM
#6360 vorlon1966 08/20/14 11:10:06 AM
#6359   Heres something about Aurobindo from april. 123tom 08/19/14 09:43:59 PM
#6358   Interesting India Fact vorlon1966 08/19/14 09:10:10 PM
#6357   Dont worry fellas i will sell tomorrow, and bleach_ 08/19/14 06:33:59 PM
#6356   oops, I goofed...I didnt buy at 93 123tom 08/19/14 04:02:15 PM
#6355   @snidely..."if I buy at 96 it will 123tom 08/19/14 03:28:56 PM
#6354   Lol snidely 08/19/14 10:20:30 AM
#6353   please do not buy then, I'm in at gdog 08/19/14 10:20:18 AM
#6352   Waiting to re-enter myself. If I buy at snidely 08/19/14 10:18:39 AM
#6351   Ya even i find it hard to be EODparty7 08/19/14 03:47:03 AM
#6350   worth a repost: buccaneer1961 08/19/14 02:04:25 AM
#6349   I like this part Paulness 08/18/14 07:47:13 PM
#6348   Anything I post is just a guess since vorlon1966 08/18/14 05:04:32 PM
#6347   @Voloron What do you think the timeline is ashferna 08/18/14 04:17:44 PM
#6346   Watching this pop and the price action now.... 123tom 08/18/14 02:45:28 PM
#6345   The next news that should come out soon: vorlon1966 08/18/14 01:20:02 PM
#6344   It's called venting. I do it too but vorlon1966 08/18/14 01:10:01 PM
#6342   I don't see a problem with the PR. vorlon1966 08/18/14 12:36:09 PM
#6341   Well, thanks for the info on the Chinese company 236T568 08/18/14 12:03:57 PM
#6340   July 7, 2014. FT Chinese simultaneously released the Paulness 08/18/14 12:00:33 PM
#6339   I'm sorry but what part of the bottom 236T568 08/18/14 11:20:47 AM
#6338   I'll have to re-read that article again. G Bert 08/18/14 11:16:06 AM
#6337   Why isn't it listed on the PVCT Zooker 08/18/14 11:15:34 AM
#6336   actually, no 236T568 08/18/14 10:57:26 AM
#6335   The info you posted is from a news Zooker 08/18/14 10:54:34 AM
#6334   Sometimes yes. But in this case Sinopharm wanted vorlon1966 08/18/14 10:38:58 AM
#6333   the description of who and what happened at 236T568 08/18/14 10:29:25 AM
#6332   Network One has an expert who works closely vorlon1966 08/18/14 10:19:15 AM
#6331   So PVCT's sleazy investment bank was involved on 236T568 08/18/14 10:14:04 AM
#6330   Is everybody calm now? Once the protocols are vorlon1966 08/18/14 10:03:12 AM
#6329   Nice seeing PVCT back over a buck! I'm smitter 08/18/14 09:51:52 AM
#6328   Hope this kicks the price above $1...for good! Zooker 08/18/14 09:38:53 AM
#6327   China deal in the works, a life saver, Ovidius 08/18/14 09:20:35 AM
#6326   Re:Vorlon I'm in it for the long KPS88 08/18/14 09:08:00 AM
#6325   I don't always agree with mgt vorlon1966 08/17/14 05:23:35 PM
#6324   For years and Years the 4 employees were Ovidius 08/17/14 01:01:24 AM
#6323   well said,Vorlon.I have always believed that no one novicetrader 08/16/14 06:50:17 PM
#6322   Great post Vorlon... Gulfbreeze 08/15/14 04:31:44 PM
#6321   An upgrade from Goldman....and we'll all be looking Zooker 08/15/14 11:41:21 AM
#6320   Nice find, Z. Who's this Goldman Sachs G Bert 08/15/14 11:40:16 AM
#6319   Vorlon: You should bump your response up Zooker 08/15/14 11:27:09 AM
#6318   I somehow thought that this would come up. vorlon1966 08/15/14 11:17:00 AM
#6317   Per new CTD looks like institutions are Zooker 08/15/14 10:42:16 AM
#6316   Why I like this board: Two reasons...It's KPS88 08/15/14 09:34:43 AM